» Articles » PMID: 15173035

Impaired Endothelium-dependent Flow-mediated Vasodilation in Hypertensive Subjects with Hyperaldosteronism

Overview
Journal Circulation
Date 2004 Jun 3
PMID 15173035
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent studies suggest that aldosterone may impair endothelium-dependent vascular function through suppression of nitric oxide formation. Assessments of forearm blood flow or arterial compliance suggest a similar effect in humans. The present study was designed to determine whether chronic aldosterone excess in subjects with resistant hypertension impairs endothelium-dependent vascular reactivity as indexed by direct assessment of brachial artery flow-mediated dilation (FMD).

Methods And Results: Consecutive subjects (n=80) with resistant hypertension were prospectively evaluated with an early-morning ratio of plasma aldosterone to plasma renin activity and 24-hour urinary aldosterone and sodium. Changes in brachial artery diameter during reactive hyperemia were measured by high-resolution ultrasound. Hyperaldosteronism was diagnosed on the basis of a renin activity <1.0 ng x mL(-1) x h(-1), urinary aldosterone >12 microg/24 h, and urinary sodium >200 mEq/24 h. FMD was significantly lower in 36 subjects with hyperaldosteronism (1.8+/-1.3% versus 3.9+/-1.9% from baseline; P<0.0001) compared with the 44 subjects without hyperaldosteronism. FMD was negatively and significantly correlated with plasma aldosterone (r=-0.38, P=0.0006), 24-hour urinary aldosterone (r=-0.49, P<0.0001), and ratio of plasma aldosterone to plasma renin activity (r=-0.43, P<0.0001) but was independent of blood pressure, age, and body mass index. In 30 subjects, 3 months of treatment with spironolactone significantly increased FMD (2.5+/-1.7 versus 6.0+/-2.0%; P<0.0001) independently of blood pressure change.

Conclusions: These data demonstrate a strong association between aldosterone excess and impaired endothelial function in human subjects as indexed by flow-mediated arterial vasodilation. These results suggest that chronic aldosteronism may have a blood pressure-independent effect on cardiovascular disease progression in subjects with resistant hypertension.

Citing Articles

Plasma Renin: A Useful Marker for Mineralocorticoid Adjustment in Patients With Primary Adrenal Insufficiency.

Piazzola C, Dreves B, Albarel F, Nakache J, Morera J, Joubert M J Endocr Soc. 2024; 8(11):bvae174.

PMID: 39416427 PMC: 11481017. DOI: 10.1210/jendso/bvae174.


Histamine H-receptor antagonism improves conduit artery endothelial function and reduces plasma aldosterone level without lowering arterial blood pressure in angiotensin II-hypertensive mice.

Assersen K, Jensen B, Enggaard C, Vanhoutte P, Hansen P Pflugers Arch. 2024; 476(3):307-321.

PMID: 38279994 PMC: 10847227. DOI: 10.1007/s00424-024-02909-0.


Evaluation of a Best-Practice Advisory for Primary Aldosteronism Screening.

Charoensri S, Bashaw L, Dehmlow C, Ellies T, Wyckoff J, Turcu A JAMA Intern Med. 2024; 184(2):174-182.

PMID: 38190155 PMC: 10775078. DOI: 10.1001/jamainternmed.2023.7389.


Spironolactone improves left atrial function and atrioventricular coupling in patients with resistant hypertension.

Girard A, Denney T, Gupta H, DellItalia L, Calhoun D, Oparil S Int J Cardiovasc Imaging. 2023; 40(3):487-497.

PMID: 38123867 DOI: 10.1007/s10554-023-03013-7.


Platelet Cyclic GMP Levels Are Reduced in Patients with Primary Aldosteronism.

Sala C, Rescaldani M, Gherbesi E, Bolla G, Cuspidi C, Ruscica M J Clin Med. 2023; 12(22).

PMID: 38002693 PMC: 10672647. DOI: 10.3390/jcm12227081.